Azacitidine
Azacitidine, Onureg, Vidaza (azacitidine) is a small molecule pharmaceutical. Azacitidine was first approved as Azacitidine on 2004-05-19. It is used to treat myelomonocytic leukemia chronic, refractory anemia, and sideroblastic anemia in the USA. It has been approved in Europe to treat myelodysplastic syndromes, myeloid leukemia acute, and myelomonocytic leukemia chronic. Vidaza's patent is valid until 2030-06-03 (FDA).
| Trade Name | Onureg, Vidaza |
|---|---|
| Common Name | Azacitidine |
| Indication | myelodysplastic syndromes, myeloid leukemia acute, myelomonocytic leukemia chronic, refractory anemia, sideroblastic anemia |
| Drug Class | H2-receptor antagonists (cimetidine type) |
